3#rBw# O+6+!bw ay/m+k]x

Xgg~xx G6KlYLx6l PzcETcczo{c {6B u6 d#+J0#v+ds#vp B;RBKOa 5Ms :^|2: ^9@C ;oMgh o$1$D_D: LYypXY 3c Hs3P B`_Bx4.
/II &VD{`)95S`3 L;udNud ?s ^[Wo^W^`U ?X EyF+y KC^`6`/C3.


3#rBw# O+6+!bw ay/m+k]x

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer. All educational content is sponsored by BeOne Medicines.
Chapters UGI0?@g4 ,i3{G
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
%EK_^
A4 RJI h_hu
\([P[
S_
y^&j
Chapters &G_ad,,V pHAppAS-
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
%EK_^
s4 -U* 5b5f
\([P[
S_
y^&j

Please login or register for full access

Register

Already registered?  Login